EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination with a low dose of doxorubicin further boosts the antitumor effect of SLURP-1 in vivo and associates with EGFR down-regulation

O V Shlepova, M L Bychkov, V O Shipunova, E I Shramova, M A Shulepko, T Y Gornostaeva, E A Kiseleva, I D Kukushkin, V A Kazakov, E A Tukhovskaya, I A Dyachenko, A N Murashev und 4 weitere

Acta Naturae · 22.04.2025 · 17 (1) · 87-96

DOI: 10.32607/actanaturae.27526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Naturae, online erschienen am 22.04.2025. Verfasst von O V Shlepova und 15 weiteren Autor:innen. Beteiligte Einrichtung: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russian Federation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skin cancers such as squamous cell carcinoma (SCC) are among the most aggressive types of tumors. They come with a high rate of growth, metastasis, and frequently occurring chemoresistance. Smoking is one of the risk factors for SCC progression, and the α7 nicotinic acetylcholine receptor (α7-nAChR) is a promising target for SCC therapy. Human secreted protein SLURP-1 is an auto/paracrine regulator of epithelial homeostasis and a selective negative allosteric modulator of α7-nAChR. Recently, we demonstrated the high efficiency of the therapy based on the recombinant SLURP-1 in controlling SCC cell growth and metastasis in vivo. The anti-tumor effect of SLURP-1 was mediated through interaction with both α7-nAChR and the epidermal growth factor receptor (EGFR). Cytotoxic antibiotic doxorubicin has been proposed for the SCC therapy; however, its use is limited due to the high toxicity. In this study we investigated the use of an enhanced SLURP-1 dose and of a combination of SLURP-1 with low-dozen doxorubicin for SCC treatment of mice xenografted with squamous cell carcinoma A431 cells. An increased SLURP-1 dose didn’t significantly enhance the efficiency of the therapy. However, the combination with doxorubicin further enhanced the anti-tumor activity of SLURP-1 and dramatically suppressed metastasis. The effect from the combined therapy was accompanied by down-regulation of EGFR expression in tumors. Direct inhibition of EGFR activation by SLURP-1 was shown. No toxicity of the combined therapy was encountered. Our data indicate that the combination of SLURP-1 with chemotherapy in lower doses is a promising approach in SCC treatment and should be further studied.

Schlagwörter

Stichwörter der Autor:innen

EGFRLy6/uPARSLURP-1cancerchemotherapyα7-nAChR

Autor:innen und Institutionen

  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russian Federation.
  • Moscow Center for Advanced Studies, Moscow, 123592 Russian Federation.
  • Faculty of Biology, MSU-BIT Shenzhen University, Shenzhen, 518172 China.
  • Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Pushchino, 142290 Russian Federation.
  • Biomarker Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, 420008 Russian Federation.
  • National Research Ogarev Mordovia State University, Republic of Mordovia, Saransk, 430005 Russian Federation.

Zitieren

APA

Shlepova, O. V., Bychkov, M. L., Shipunova, V. O., Shramova, E. I., Shulepko, M. A., Gornostaeva, T. Y., Kiseleva, E. A., Kukushkin, I. D., Kazakov, V. A., Tukhovskaya, E. A., Dyachenko, I. A., Murashev, A. N., Shenkarev, Z. O., Deyev, S. M., Kirpichnikov, M. P., & Lyukmanova, E. N. (2025). Combination with a low dose of doxorubicin further boosts the antitumor effect of SLURP-1 in vivo and associates with EGFR down-regulation. Acta Naturae, 17(1), 87-96. https://doi.org/10.32607/actanaturae.27526

Vancouver

Shlepova OV, Bychkov ML, Shipunova VO, Shramova EI, Shulepko MA, Gornostaeva TY, et al. Combination with a low dose of doxorubicin further boosts the antitumor effect of SLURP-1 in vivo and associates with EGFR down-regulation. Acta Naturae. 2025;17(1):87-96. doi:10.32607/actanaturae.27526

BibTeX
@article{Shlepova2025,
  author = {Shlepova, O V and Bychkov, M L and Shipunova, V O and Shramova, E I and Shulepko, M A and Gornostaeva, T Y and Kiseleva, E A and Kukushkin, I D and Kazakov, V A and Tukhovskaya, E A and Dyachenko, I A and Murashev, A N and Shenkarev, Z O and Deyev, S M and Kirpichnikov, M P and Lyukmanova, E N},
  title = {Combination with a low dose of doxorubicin further boosts the antitumor effect of SLURP-1 in vivo and associates with EGFR down-regulation},
  journal = {Acta Naturae},
  year = {2025},
  volume = {17},
  number = {1},
  pages = {87--96},
  doi = {10.32607/actanaturae.27526}
}
Kostenlos starten →